T. Rowe Price Associates’s CVS Health CVS Stock Holding History

T. Rowe Price Associates’s Portfolio CVS Stock Details CVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.71B	Buy	23,783,145 +7,339,159	+45%	+$565M	0.2%	106
2025 Q4	$1.3B	Sell	16,443,986 -953,749	-5%	-$75.2M	0.14%	132
2025 Q3	$1.31B	Buy	17,397,735 +784,591	+5%	+$53.8M	0.14%	130
2025 Q2	$1.15B	Buy	16,613,144 +1,303,855	+9%	+$85.5M	0.13%	151
2025 Q1	$1.04B	Buy	15,309,289 +1,942,886	+15%	+$116M	0.13%	157
2024 Q4	$600M	Buy	13,366,403 +1,660,321	+14%	+$93.1M	0.07%	243
2024 Q3	$736M	Buy	11,706,082 +1,469,710	+14%	+$85.7M	0.08%	219
2024 Q2	$605M	Sell	10,236,372 -462,662	-4%	-$28.9M	0.07%	236
2024 Q1	$853M	Buy	10,699,034 +13,268	+0.1%	+$1.01M	0.1%	182
2023 Q4	$844M	Sell	10,685,766 -21,271	-0.2%	-$1.51M	0.11%	180
2023 Q3	$748M	Buy	10,707,037 +942,795	+10%	+$66.8M	0.11%	189
2023 Q2	$675M	Buy	9,764,242 +857,471	+10%	+$61M	0.09%	206
2023 Q1	$662M	Sell	8,906,771 -1,708,750	-16%	-$143M	0.1%	203
2022 Q4	$989M	Buy	10,615,521 +1,006,358	+10%	+$97.1M	0.16%	137
2022 Q3	$916M	Sell	9,609,163 -202,085	-2%	-$20M	0.15%	140
2022 Q2	$909M	Sell	9,811,248 -384,640	-4%	-$37.5M	0.11%	193
2022 Q1	$1.03B	Sell	10,195,888 -291,416	-3%	-$30.6M	0.1%	201
2021 Q4	$1.08B	Sell	10,487,304 -137,315	-1%	-$12.7M	0.1%	207
2021 Q3	$902M	Sell	10,624,619 -2,314,962	-18%	-$194M	0.08%	244
2021 Q2	$1.08B	Buy	12,939,581 +903,835	+8%	+$74M	0.1%	211
2021 Q1	$905M	Sell	12,035,746 -1,872,247	-13%	-$136M	0.09%	238
2020 Q4	$950M	Sell	13,907,993 -3,326,130	-19%	-$216M	0.1%	217
2020 Q3	$1.01B	Sell	17,234,123 -3,976,762	-19%	-$247M	0.12%	186
2020 Q2	$1.38B	Buy	21,210,885 +1,780,972	+9%	+$112M	0.17%	123
2020 Q1	$1.15B	Buy	19,429,913 +312,203	+2%	+$20.8M	0.18%	122
2019 Q4	$1.42B	Sell	19,117,710 -73,790	-0.4%	-$5.18M	0.18%	120
2019 Q3	$1.21B	Buy	19,191,500 +544,992	+3%	+$32.3M	0.17%	137
2019 Q2	$1.02B	Sell	18,646,508 -5,969,039	-24%	-$321M	0.14%	160
2019 Q1	$1.33B	Buy	24,615,547 +1,582,706	+7%	+$97.7M	0.2%	119
2018 Q4	$1.51B	Buy	23,032,841 +1,882,778	+9%	+$141M	0.26%	99
2018 Q3	$1.66B	Sell	21,150,063 -2,259,808	-10%	-$162M	0.24%	97
2018 Q2	$1.51B	Buy	23,409,871 +2,725,971	+13%	+$180M	0.23%	106
2018 Q1	$1.29B	Buy	20,683,900 +5,597,820	+37%	+$402M	0.2%	111
2017 Q4	$1.09B	Buy	15,086,080 +6,320,630	+72%	+$460M	0.18%	128
2017 Q3	$713M	Buy	8,765,450 +458,135	+6%	+$36.2M	0.12%	182
2017 Q2	$668M	Buy	8,307,315 +985,144	+13%	+$77.8M	0.12%	199
2017 Q1	$575M	Sell	7,322,171 -222,033	-3%	-$17.7M	0.11%	220
2016 Q4	$595M	Sell	7,544,204 -6,855,888	-48%	-$555M	0.12%	204
2016 Q3	$1.28B	Buy	14,400,092 +4,699,619	+48%	+$444M	0.26%	92
2016 Q2	$929M	Sell	9,700,473 -7,147,975	-42%	-$712M	0.2%	130
2016 Q1	$1.75B	Sell	16,848,448 -1,755,958	-9%	-$171M	0.37%	56
2015 Q4	$1.82B	Sell	18,604,406 -3,375,033	-15%	-$331M	0.38%	61
2015 Q3	$2.12B	Buy	21,979,439 +1,899,084	+9%	+$200M	0.47%	43
2015 Q2	$2.11B	Buy	20,080,355 +1,691,641	+9%	+$173M	0.43%	48
2015 Q1	$1.9B	Sell	18,388,714 -499,374	-3%	-$50.5M	0.39%	56
2014 Q4	$1.82B	Sell	18,888,088 -2,133,178	-10%	-$188M	0.39%	52
2014 Q3	$1.67B	Buy	21,021,266 +593,131	+3%	+$46.8M	0.37%	60
2014 Q2	$1.54B	Buy	20,428,135 +2,514,316	+14%	+$190M	0.33%	69
2014 Q1	$1.34B	Buy	17,913,819 +1,795,447	+11%	+$127M	0.3%	78
2013 Q4	$1.15B	Buy	16,118,372 +156,689	+1%	+$10.1M	0.26%	91
2013 Q3	$906M	Sell	15,961,683 -355,416	-2%	-$21.2M	0.23%	114
2013 Q2	$933M	Buy	+16,317,099	New	+$945M	0.25%	101

Other funds holding CVS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates's CVS Position: Q1 2026 in Review

T. Rowe Price Associates increased its CVS Health (CVS) stake by 45% in Q1 2026, buying an estimated $565M and bringing the position to 23,783,145 shares worth $1.71B. The position accounts for 0.2% of the portfolio, ranked #106.

T. Rowe Price Associates first reported a position in CVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.12B in Q3 2015. 1,865 funds tracked by Wall St. Rank hold CVS as of Q1 2026.

T. Rowe Price Associates held 23,783,145 shares of CVS Health worth $1.71B as of Q1 2026.
T. Rowe Price Associates bought 7,339,159 CVS Health shares in Q1 2026, an estimated $565M.
CVS Health made up 0.2% of T. Rowe Price Associates's portfolio in Q1 2026, its #106 holding.
T. Rowe Price Associates first reported a position in CVS Health in Q2 2013 and has held it in 52 quarters since.
T. Rowe Price Associates's CVS Health position peaked at $2.12B in Q3 2015.
1,865 funds tracked by Wall St. Rank held CVS Health as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.